NEW YORK (GenomeWeb) – Opko Health yesterday reported a massive jump in third quarter revenues as the company benefitted from its recent acquisitions of clinical lab Bio-Reference Laboratories and specialty pharmaceutical manufacturer EirGen earlier this year.

For the three-month period ended Sept. 30, Miami, Florida-based Opko reported consolidated revenues of $143 million compared with $19.8 million in the same period last year, in line with analysts' consensus estimate. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.